Intuitive Surgical
ISRG
$375.20
+1.88%
Intuitive Surgical Inc. is a global leader in robotic-assisted minimally invasive surgery, primarily known for its da Vinci surgical systems, along with the instruments, accessories, and services that support them. The company has installed over 10,000 da Vinci systems worldwide, with a dominant market share in the U.S. and expanding presence in emerging markets, making it the undisputed market leader in surgical robotics. Currently, the stock is under pressure due to management's decision not to raise full-year guidance after a strong Q2, signaling potential growth deceleration, while also facing regulatory scrutiny over a stapler safety concern and increasing competition from Medtronic's Hugo robot. Despite these headwinds, the company's entrenched market position and continued innovation in digital surgery and AI-driven tools remain central to the long-term investment debate.…
ISRG
Intuitive Surgical
$375.20
Related headlines
Investment Opinion: Should I buy ISRG Today?
Based on the analysis, I rate ISRG as a 'Hold' with a cautious bias. The company's dominant market position and strong growth (22.96% YoY) are offset by a high valuation (PE 70.8x) and near-term headwinds. The analyst consensus is 'Buy' with an average target of $477.25, implying 35% upside, but the stock's recent downtrend and guidance concerns warrant caution.
Sign up to view all
ISRG 12-Month Price Forecast
The AI assessment is neutral with medium confidence. While the company's fundamentals are solid, the valuation is stretched, and near-term risks are elevated. The stock's technical downtrend and management's cautious guidance suggest that the market is pricing in a slowdown. If the company can deliver on its growth targets and resolve regulatory issues, the stock could recover; otherwise, it may continue to underperform. Key factors to watch include the next earnings report, FDA decisions, and competitive developments.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Intuitive Surgical's 12-month outlook, with a consensus price target around $477.25 and implied upside of +27.2% versus the current price.
Average Target
$477.25
0 analysts
Implied Upside
+27.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$324 - $685
Analyst target range
ISRG is covered by 29 analysts, with a consensus recommendation of 'Buy' and a mean recommendation score of 1.82 (where 1 is Strong Buy and 5 is Sell). The average price target is $477.25, implying a 35.1% upside from the current price of $353.33, which suggests that analysts see significant value at current levels. The target range is wide, from a low of $324.00 to a high of $685.00, indicating high uncertainty about the stock's future performance. The low target implies a further 8.3% downside, while the high target suggests a 93.9% upside, reflecting divergent views on the impact of competitive threats, regulatory issues, and the company's ability to sustain growth. Recent ratings have been mostly positive, with firms like TD Cowen, RBC Capital, and B of A Securities maintaining Buy or Outperform ratings, but the lack of guidance raises and the FDA safety concern have introduced caution, as seen in Mizuho's Neutral stance.
Bulls vs Bears: ISRG Investment Factors
Intuitive Surgical presents a classic growth-at-a-reasonable-price dilemma. On the bull side, the company boasts a dominant market position, robust revenue growth of 22.96% YoY, and high profitability with a 66% gross margin. On the bear side, the stock's valuation remains elevated (PEG 3.17), regulatory concerns loom, and management's cautious guidance suggests growth may slow. Currently, the bear case has stronger evidence in the near term, as the stock's technical downtrend and guidance concerns outweigh the fundamental strengths. The most critical tension is whether the company can sustain its high growth rate to justify its premium valuation; if growth decelerates, the stock could face further de-rating, but if growth persists, the current price may offer a compelling entry point.
Bullish
- Dominant Market Position with 10,000+ Installed Systems: Intuitive Surgical has over 10,000 da Vinci systems installed globally, with more than 6,000 in the U.S., creating a massive installed base that generates recurring revenue from instruments and services. This entrenched position provides a significant competitive moat against new entrants like Medtronic's Hugo, which only recently received FDA approval.
- Strong Revenue Growth with 22.96% YoY Increase: Q1 2026 revenue reached $2.77 billion, up 22.96% year-over-year, accelerating from Q4 2025's 18.8% growth. This robust growth is driven by strong demand for instruments and accessories ($1.69 billion) and services ($434 million), indicating healthy procedure volume expansion.
- High Profitability with 66% Gross Margin: Gross margin stands at 66.06% in Q1 2026, with operating margin at 29.27% and net margin at 28.38%. These metrics reflect the company's pricing power and operational efficiency, supporting strong free cash flow generation of $2.83 billion TTM.
- Analyst Consensus 'Buy' with 35% Upside: With 29 analysts, the consensus recommendation is 'Buy' (mean score 1.82), and the average price target is $477.25, implying a 35.1% upside from the current price of $353.33. This suggests that despite recent sell-off, analysts see significant value at current levels.
Bearish
- Guidance Not Raised Despite Strong Q2: Management's decision not to raise full-year guidance after a strong Q2 signals potential growth deceleration, which triggered a sharp stock drop. This suggests that even strong near-term results may not be sustainable, raising concerns about future revenue growth.
- Elevated Valuation with PEG of 3.17: The trailing PE is 70.8x and forward PE is 29.3x, both well above the sector average of 22x. The PEG ratio of 3.17 indicates the stock is expensive relative to its growth rate, leaving little room for error in execution.
- Regulatory Scrutiny Over Stapler Safety: The FDA flagged a safety concern over Intuitive's stapler, which could lead to product recalls, reputational damage, and potential financial penalties. This regulatory overhang adds uncertainty to the investment thesis.
- Intensifying Competition from Medtronic's Hugo: Medtronic's Hugo robot received FDA approval, marking a major milestone. While Intuitive's installed base is a barrier, increased competition could pressure pricing and market share in the long term.
ISRG Technical Analysis
ISRG is in a pronounced downtrend, with the stock price at $353.33 as of July 31, 2026, down 26.6% over the past year and 37.1% year-to-date. The current price sits at only 8.5% above its 52-week low of $328.57, while being 41.5% below its 52-week high of $603.88, indicating that the stock is trading near the bottom of its range, which could suggest a potential value opportunity or a falling knife depending on fundamental catalysts. The stock's relative strength versus the S&P 500 is deeply negative, with a 1-year relative strength of -44.7%, underscoring significant underperformance.
Beta
1.46
1.46x market volatility
Max Drawdown
-44.0%
Largest decline past year
52-Week Range
$329-$604
Price range past year
Annual Return
-21.3%
Cumulative gain past year
| Period | ISRG Return | S&P 500 |
|---|---|---|
| 1m | -13.3% | +2.5% |
| 3m | -17.3% | +5.2% |
| 6m | -23.1% | +11.5% |
| 1y | -21.3% | +22.6% |
| ytd | -33.2% | +12.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ISRG Fundamental Analysis
ISRG's revenue growth remains robust, with Q1 2026 revenue of $2.77 billion, up 22.96% year-over-year, and a sequential acceleration from Q4 2025's $2.87 billion (which was up 18.8% YoY). The growth is driven by strong demand for instruments and accessories ($1.69 billion) and services ($434 million), while systems revenue ($651 million) also contributes. However, the market is concerned about growth sustainability, as management did not raise full-year guidance despite the strong quarter, suggesting a potential slowdown in the coming quarters.
Quarterly Revenue
$2.8B
2026-03
Revenue YoY Growth
+23.0%
YoY Comparison
Gross Margin
66.1%
Latest Quarter
Free Cash Flow
$2.8B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ISRG Overvalued?
Given ISRG's positive net income, the PE ratio is the primary valuation metric. The trailing PE stands at 70.8x, while the forward PE is 29.3x, implying that the market expects significant earnings growth (a 59% premium to the sector's average PE of 22x). The gap between trailing and forward PE suggests the market is pricing in a substantial acceleration in EPS, which is supported by analyst estimates of $17.00 for the current fiscal year, up from $2.31 in Q1 2026 alone. However, the PEG ratio of 3.17x indicates that the stock is not cheap relative to its growth rate, and the PS ratio of 20.1x is also elevated, reflecting the market's high expectations for the company's future profitability.
PE
70.8x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 49x~85x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
49.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are moderate but notable. The company has a very low debt-to-equity ratio of 0.017, indicating minimal leverage, and a current ratio of 4.87, providing ample liquidity. However, the high valuation (PE 70.8x trailing) leaves little margin for error; any earnings miss could trigger a sharp sell-off. Revenue concentration in the U.S. (over 60% of installed base) exposes the company to domestic healthcare policy changes, while the reliance on recurring instrument sales means procedure volume is key. The free cash flow of $2.83 billion TTM is strong, but the company's heavy R&D spending (13% of revenue) is essential to maintain its competitive edge, and any disruption in innovation could impact future growth.